Literature on the behavior of cystic lesions in pancreas transplants is scarce, and hence a better understanding is warranted. Data on recipients and their respective donors that underwent simultaneous kidney and pancreas, pancreas transplant alone, and pancreas after kidney between 1994 and 2015 were reviewed (n = 1185). Cystic lesions of the transplant pancreas developed in 22 patients (1.8%): 12 pseudocysts, 2 cysts/remnants, 4 intraductal papillary mucinous neoplasms (IPMN), 2 adenocarcinomas, 1 low-grade intraepithelial pancreatic neoplasia, and 1 case of polycystic kidney disease. The median size was 3.6 cm (1.6-5.5 cm), and occurred at a median time of 65.5 months (2-183 months) posttransplant. The median age of the graft at time of diagnosis was 42 years (25.7-54.5), with 17 of 22 grafts (77%) functioning at time of diagnosis. Triggers for investigation were elevations in pancreatic enzymes, readmissions for abdominal pain, and incidentalomas. High-resolution imaging and diagnostic biopsy/aspiration with ancillary tests were the main diagnostic tests. Most pseudocysts were managed by percutaneous drainage, and although no firm inference can be made from such a small series, we have observed that the behavior and management of IPMN and adenocarcinoma in the pancreas graft appears congruent to that of the native pancreas.
on high-risk and worrisome features from the Fukuoka guidelines.
While not specified in these guidelines, risk factors, tumor markers, and cyst aspiration for biochemical and genetic analysis have also further magnified our understanding of these lesions. 8, 9 PCL in recipients of solid organ transplant (SOT) patients have been studied, with a prevalence of 6.6%-11.4% similar to the general nontransplant population. 10, 11 Among SOT recipients, PCL seemingly occur most commonly in liver transplant recipients (14.9%) followed by combined organ transplants (12.7% ). It appears that in SOT recipients, PCL lesions without high-risk features have a very low malignant potential, and these lesions can be managed conservatively as in the general population. 10, 11 In contrast, the prevalence of PCL in the transplant pancreas (TPCL) confounded by a nonorthotopic position and immunosuppressed state is unknown, and hence an understanding is warranted. We present here a series of TPCL cases from a high-volume center to shed light on the epidemiology of TPCL in pancreas transplant recipients.
| MATERIALS AND METHODS

Using databases of the University of Wisconsin Transplant Surgery
Division, we retrospectively reviewed data on all the pancreas trans- Descriptive data analysis included calculations of proportions, percentages, medians, and interquartile ranges (25th-75th percentile).
Mann-Whitney and chi-square tests were performed to compare the demographic data between the group with and without TPCL.
Eligibility for diagnosis of a TPCL was based on database coding of "cyst of transplant pancreas." Each chart was then reviewed, and records of cross-sectional imaging were searched for the diagnosis of pancreatic cysts/lesions of the transplant pancreas. Manual review of radiographic imaging to confirm the presence of TPCL was performed, along with manual measurement of the cyst/lesion size and consolidated with the final report. Size at diagnosis, and at each follow-up was recorded. The worrisome and high-risk features from the Fukuoka guidelines were used to guide our management of IPMN. In the absence of typical imaging features, the lesions were considered indeterminate and managed on a case-by-case basis. Indications for cyst aspiration/biopsy were elevated pancreatic enzymes, symptoms, and worrisome features/growth kinetics of the cyst. 
| RESULTS
A total of 1185 pancreas transplants performed between 1994 and 2014 were reviewed. Overall, 22 patients had evidence of at least 1 cystic/mixed lesion of the transplanted pancreas, yielding a prevalence of 1.8%. The demographic data of the whole cohort comparing those without TPCL vs those with TPCL are presented in Table 1 . Of the lesions identified, 20 were benign (91%), and 2 were malignant (9%).
The different diagnoses included a total of 12 pseudocysts, 2 cysts/ remnants, 4 IPMNs, 2 primary adenocarcinomas, 1 low-grade intraepithelial pancreatic neoplasia, and 1 case of polycystic kidney disease with cystic involvement in both the transplant kidney and pancreas in a SPK patient ( Table 2 ). The indications prompting workup are outlined in Table 2 . The median time from transplant to diagnosis of TPCL was 65.5 months (2-183 months). Most patients had 1 lesion in the pancreas (median 1, range 1-5), with a median size of 3.6 cm (1.6-5.5 cm).
The median amylase and lipase at time of diagnosis were 111 U/L (normal range 25-125 U/L) and 443.5 U/L (normal range 8-78 U/L). Cyst aspiration/drainage was performed in 9 subjects (41%) with data on amylase, cytology, and carcinoembryonic antigen (CEA) levels. Tumor markers, CEA and CA19-9, were available in 6 patients (27%). Median follow-up times from date of transplant and from date of diagnosis of these lesions were 91 months (43-183 months) and 14.5 months (4-52.5 months), respectively. At the time of TPCL diagnosis, 17 recipients (77%) had a normal functioning graft displaying excellent glycemic control, with a median HbA1C of 5.8% (5.3%-6.8%), median fasting C peptide of 2.9 ng/mL (2-5.8 ng/mL), and median glucose of 110 mg/dL (92-123 mg/dL) ( Table 3 ). At time of last follow-up, 15 (68%) were alive with 9 patients (41%) having a functioning graft (Table 3) .
| Pancreatic pseudocysts and cystic remnants
Twelve of 22 (55%) TPCLs were pseudocysts of the pancreas graft (Figures 1-3 
| Intraductal papillary mucinous neoplasms (IPMN)
Four
| Primary pancreatic adenocarcinoma
Two cases of adenocarcinoma were diagnosed accounting for 9% of 
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T A B L E 3 Graft status at time of diagnosis of TPCL, metabolic profile, and outcomes 
| Other diagnoses
A diagnosis of polycystic kidney disease involving both the transplanted kidney and pancreas was seen in subject 16. Cyst aspiration showed negative cytology, CEA 15.9 ng/mL, amylase 10 U/L, and serum CA 19-9 of 4 U/mL. In subject 14, low-grade intraepithelial pancreatic neoplasia was diagnosed on retransplant as a transplant pancreatectomy of the previous graft was performed to accommodate. Both kidney and pancreas remain functioning in subject 16, and the second pancreas graft performed for subject 14 remains functioning to date. 
| DISCUSSION
In this large series of pancreas transplants, the prevalence of pancreatic cystic lesions in the transplanted pancreas was 1.8%. The reported prevalence of pancreatic cysts in the native pancreas is higher and varies widely depending on the modality of diagnosis; 2.6% in a CT study, 13 .5% in an MRI study, and on autopsy as high as 24%. [12] [13] [14] Most of these lesions in our cohort were benign in nature, were managed either conservatively or by minimally invasive means, and did not show significant growth over a median follow-up of 14.5 months from the time of diagnosis. With increased frequency of high-resolution imaging in nontransplanted patients, PCL are being seen with increasing frequency (incidentalomas), and pancreas transplant recipients are also frequently imaged for abdominal symptoms or laboratory abnormalities throughout their posttransplant course; it is not unexpected that more TPCL will be detected. Similarly, lack of systematic/standardized imaging underestimates the true incidence of these lesions. Risk factors for TPCL have not been evaluated to date owing to their low frequency.
In our series, pancreatic transplant pseudocyst appeared to be related to episodes of rejection, graft biopsy, and/or pancreatitis; however, a precise causal relationship is difficult to determine. No clinical factors or patterns were observed in patients with IPMN and other diagnoses.
In the native pancreas, pancreatic pseudocysts are the most common form of cysts, comprising 75% of all cystic lesions of the pancreas, of which 15% are neoplastic, [15] [16] [17] ; hence a misdiagnosis of a neoplastic cyst as a pseudocyst can occur. 18, 19 This compares to our cohort where the majority of TPCL were benign pseudocysts (16/22; 73%) and 27% (6/22) were neoplastic, benign, or malignant. Sorting through the differential diagnosis of TPCL can present a diagnostic challenge.
We were unable to identify predictors of benignity vs malignancy to help guide management. For example, cyst number, size, time from transplant, or age of the graft was not associated with a particular diagnosis. Furthermore, endoscopic ultrasound (EUS)/fine-needle aspiration are difficult to achieve in the jejunally drained pancreatic allograft. However, novel techniques such as duodenal enteric drainage to the distal or postpyloric duodenum may be amenable to EUS or BD-IPMNs demonstrated a low rate of progression to malignancy, 0% to 3.7%, after an average follow-up of 23 months to 8 years. 28, 29 Although our series is small, we have observed a similar behavior of IPMNs among our cohort. With respect to the 2 cases of pancreatic adenocarcinoma, and in congruence with the management in the native pancreas, surgical resection is the only potentially curative approach. 30 Both of our patients were managed via a multidisciplinary approach, and as one would predict, the subject with metastatic pancreatic cancer had poor survival. Subject 3 remains alive nearly 3 years from diagnosis and surgical extirpation with no evidence of disease recurrence/metastases and a normal CA19-9 level, which declined from 2698 U/mL at diagnosis to 19 U/mL on last follow-up.
To our knowledge, this is the only series of pancreatic cystic lesions in the transplanted pancreas. Based on our limited experience, we propose an algorithm to approach these lesions as shown in Figure 6 . As with any retrospective study, our study inherently has multiple lim- 
| CONCLUSION
The prevalence of TPCLs in pancreatic transplants is rare. Most of the cysts were benign, and remained unchanged in morphology and size on follow-up; the progressive development of worrisome features for cancer was also a rare event. Despite their rarity, our experiencebased recommendations for work-up and diagnosis includes history, CT, MRI imaging, and cyst fluid sampling and/or biopsy where possible. It also suggests that the behavior and management of IPMNs and adenocarcinoma in the pancreas graft appear congruent to those diagnoses of the native pancreas. Moreover, we believe management of pseudocysts should first be managed by percutaneous aspiration or drainage to aid in diagnosis and distinguish from enteric leak in symptomatic patients but do not commonly need surgical drainage.
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